Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization

about

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.

P2860

Q37019034-25CC7B9E-649C-4A40-B5B7-5C9EB827B83A Q37397624-E8130ED2-905E-47CA-A34F-E268536C5BCA

P2860

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization

Item

http://www.wikidata.org/entity/Q36635004

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Partial Response to Platinum D ...... : Evidence of Episensitization

@ast

Partial Response to Platinum D ...... : Evidence of Episensitization

@en

type

Item

label

Partial Response to Platinum D ...... : Evidence of Episensitization

@ast

Partial Response to Platinum D ...... : Evidence of Episensitization

@en

prefLabel

Partial Response to Platinum D ...... : Evidence of Episensitization

@ast

Partial Response to Platinum D ...... : Evidence of Episensitization

@en

P1476

Partial Response to Platinum D ...... : Evidence of Episensitization

@en

P2093

Aiste Degesys

http://www.w3.org/2001/XMLSchema#string

Bryan T Oronsky

http://www.w3.org/2001/XMLSchema#string

Christina Brzezniak

http://www.w3.org/2001/XMLSchema#string

Corey A Carter

http://www.w3.org/2001/XMLSchema#string

Jan J Scicinski

http://www.w3.org/2001/XMLSchema#string

John Jenkins

http://www.w3.org/2001/XMLSchema#string

Tony Reid

http://www.w3.org/2001/XMLSchema#string

P2860

Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-Distance

Rewriting the epigenetic code for tumor resensitization: a review.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Erlotinib in previously treated non-small-cell lung cancer

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Epigenetics in cancer

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.

Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.

P304

62-67

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000443725

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Pedro Cabrales

Scott Caroen

P577

2016-01-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26933421

http://www.w3.org/2001/XMLSchema#string

P932

4772628

http://www.w3.org/2001/XMLSchema#string

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization

about

P2860

P2860

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932